Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

To learn more, please visit www.reprievetrial.org.

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

Can Gilead be held accountable for holding back the sale of an HIV drug it allegedly knew was safer than its blockbuster predecessor? The answer could offer a unique example of a situation where a ...

Josh Brown, CEO of Ritholtz Wealth Management, said during a program on CNBC last month that he’s paying attention to Gilead Sciences Inc (NASDAQ:GILD).

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...